Novartis Pharmaceuticals Corporation has launched two new dosage strengths of its product Stalevo®, which is approved for use in treatment of Parkinson’s disease. With the approval of 75 and 125 tablets of Stalevo, physicians have another option to prescribe to patients who go through end-of-dose “wearing off”. The product simplifies treatment because it provides more sustained levodopa levels in the blood by combining it with the enzyme inhibitors carbidopa and entacapone.